Associations of herbal and specialty supplements with lung and colorectal cancer risk in the VITamins and Lifestyle study. by Satia, Jessie A et al.
 1
Associations of herbal and specialty supplements with lung and colorectal cancer risk in the 
VITamins And Lifestyle (VITAL) Study 
 
Authors’ Affiliations 
 
Jessie A. Satia, PhD, MPH 1, 2,  3, 4 
 
Alyson Littman, PhD 5, 6 
 
Christopher G. Slatore, MD, MS 7 
 
Joseph A. Galanko, PhD 4 
 
Emily White, PhD 5, 8 
 
 
1 Department of Nutrition, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, 
United States 
 
2 Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North 
Carolina, United States 
  
3 Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, 
North Carolina, United States 
 
4 Center for Gastrointestinal Biology and Disease, Division of Digestive Diseases and Nutrition, 
University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States 
 
5 Department of Epidemiology, University of Washington, Seattle, Washington, United States 
 
6 Epidemiologic Research and Information Center, VA Puget Sound Health Care System, Seattle, 
Washington, United States 
 2
7 Division of Pulmonary and Critical Care Medicine, University of Washington, Seattle, Washington, 
United States 
 
8 Cancer Prevention Program, Fred Hutchinson Cancer Research Center, Seattle, WA 
 
 
Corresponding Author who will address correspondence and request for reprints 
Jessie A. Satia, PhD, MPH 
Associate Professor, Departments of Nutrition and Epidemiology 
University of North Carolina at Chapel Hill 
Chapel Hill, NC 27599 
Phone: (919) 843-3641 
Fax: (919) 966-7217  
E-mail: jsatia@unc.edu 
 
Funding sources 
 
This study was funded by grants R01 CA74846, K22CA096556, and R03 CA 119683-01 from the 
National Cancer Institute.  
 
Running title 
Herbal and specialty supplements and lung and colorectal cancer risk 
 
Key words 
cancer; colorectal cancer; dietary supplements; herbal supplements; lung cancer; specialty supplements 
 
 3
ABSTRACT 
 
 
Millions of Americans use dietary supplements with little knowledge about their benefits or risks. We 
examined associations of various herbal/specialty supplements with lung and colorectal cancer (CRC) 
risk. Men and women, 50-76y, in the VITAL (VITamins And Lifestyle) cohort completed a 24-page 
baseline questionnaire that captured duration (years) and frequency (days/week) of use of commonly 
used herbal/specialty supplements. Dose was not assessed due to lack of accurate potency information. 
Supplement exposure was categorized as “no use” or “any use” over the previous 10 years. Hazard 
ratios (HR) were estimated by multivariate Cox regression models. Incident lung (n=665) and CRC 
cancers (n=428) were obtained from the SEER cancer registry. Any use of glucosamine and 
chondroitin, which have anti-inflammatory properties, over the previous 10 years, was associated with 
significantly lower lung cancer risk: HR: 0.74 (95% CI: 0.58, 0.94) and HR: 0.72 (95% CI: 0.54, 0.96) 
and CRC risk: HR: 0.73 (95% CI: 0.54, 0.98) and HR: 0.65 (95% CI: 0.45, 0.93), respectively. There 
were also statistically significantly inverse associations of fish oil: HR: 0.65 (95% CI: 0.42, 0.99), 
methylsulfonylmethane (MSM): HR: 0.46 (95% CI: 0.23, 0.93), and St. John’s wort:  HR: 0.35 (95% 
CI: 0.14, 0.85) with CRC risk. In contrast, garlic pills were associated with a statistically significant 
35% elevated CRC risk. These results suggest that some herbal/specialty supplements may be 
associated with lung and CRC risk; however, these products should be used with caution. Additional 
studies examining the effects of herbal/specialty supplements on risk for cancer/other diseases are 
needed. 
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INTRODUCTION 
 
There has been a substantial increase in the use of complementary and alternative medicines 
(CAM), including dietary supplements, in the United States (U.S.) since the early 1990s (1-5). In 
particular, use of herbal or other non-vitamin, non-mineral “specialty” supplements has increased more 
than use of any other CAM modality (1-6). This increased use is reflected both in sales figures and in 
self-reported use by the general population. For example, sales of dietary supplements increased from 
$8.8 billion in 1994 to $18.8 billion in 2003 (4,5), and in 2001 alone, Americans spent $4.2 billion on 
herbs and other botanical remedies (7). Kelly et al (2005) reported that in any week in 2002, 18.8% of 
American adults used a dietary supplement containing an herbal or other natural product (4). Based on 
recent trends, analysts predict that use of these supplements will continue to increase (1-6, 7, 8). 
Millions of Americans are using these herbal and specialty formulations to prevent or treat 
diseases, with very limited evidence of their benefits or risks (3-6, 8-12). Passage of the Dietary 
Supplement Health and Education Act (DSHEA) of 1994 established that dietary supplements 
(including herbal and specialty supplements) be regulated under a Food and Drug Administration 
(FDA) category separate from both foods and drugs; thus, these products undergo minimal regulation 
(12,13). Consequently, there are ongoing concerns about their safety (12-17). There are also concerns 
about their efficacy, given that relatively few randomized clinical trials have been conducted to assess 
their effects on risk for various diseases (12, 18). In addition, virtually no observational studies have 
examined whether use of these supplements is associated with risk for developing (or preventing) 
disease. Moreover, it is possible that these supplements may increase disease risk. 
There have been several reports examining trends, patterns, motivations, as well as correlates 
and predictors of herbal and specialty supplement use in the general population and persons with 
cancer (1-6, 8-12, 14, 17, 19, 20). Studies have found that consumers use herbal and specialty 
supplements with the hope of preventing diseases, including cancers (3-6, 8-12, 19, 20). Lung and 
colorectal cancers are the second and third most common cancers in the U.S., and the first and third 
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leading causes of cancer deaths, respectively (21,22). Several in vitro, cellular, and animal studies have 
evaluated the effects of herbal and other specialty products on the development and progression of 
lung and colorectal cancers (23-27); however, we are not aware of any comparable epidemiologic 
studies. Clearly, well-designed studies in human populations are critical to determining the potential 
effectiveness and/or adverse events associated with use of these products by consumers.  
In this report, we examine associations of use of the most commonly used herbal and specialty 
supplements with risk of lung and colorectal cancers using data from a large cohort study of dietary 
supplements and cancer risk.  
 
 
MATERIALS AND METHODS 
 
The VITAL Study recruitment and response rates 
The VITAL study aimed to investigate associations of dietary supplement use with cancer risk. 
Details of the study design and methods have been published (28). Cohort members were men and 
women age 50-76 at entry living in a 13-county area in western Washington State, the catchment area 
of the Seattle-Puget Sound Surveillance and End Results (SEER) cancer registry, who completed a 24-
page baseline questionnaire. Recruitment was conducted from October 2000-December 2002. 
Using names purchased from a commercial mailing list, 364,418 baseline questionnaires were 
mailed, followed by a post-card reminder after two weeks. 79,300 questionnaires were returned (21.8% 
overall, 19.5% response proportion among men, and 24.4% among women), of which 1,580 were 
ineligible and 241 failed quality control checks, leaving 77,719 eligible cohort members at baseline 
(28). The study protocol was approved by the Institutional Review Board of the Fred Hutchinson 
Cancer Research Center (Seattle, WA). 
 
Data collection 
Data were self-reported using a 24-page sex-specific, optically scanned questionnaire that 
covered three content areas: supplement use, diet, and health history and risk factors.  
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Measurement of herbal and specialty supplement use Respondents were asked about use 
(duration in years, frequency in days per week, and usual dose) of various supplements, including 
multivitamins, individual vitamin and mineral supplements, other mixtures, and herbal and specialty 
products) during the 10 years prior to baseline. Details on the validity of assessment of multivitamin 
and individual vitamin and mineral supplement use have been published (29).  
Participants reported on use of 20 herbal and specialty supplements from pills, tinctures, 
powders, and teas taken regularly (at least once a week for a year) during the previous 10 years: 16 
products taken by men and women, as well as 2 for men only (dehydroepiandrosterone, DHEA, and 
saw palmetto), and 2 for women only (black cohosh and dong quai). A closed-ended format was used 
to inquire about current versus past use, duration of use (1-2, 3-5, 6+ years), and frequency (1-2, 3-5, 
6+days per week) over the previous 10 years. Questions on dose were not included because of lack of 
accurate information on potency. Also, respondents could report on use of herbal and specialty 
supplements in the multivitamin section, as some of the multivitamins queried on included herbal 
products.  
For these analyses, due to limited distribution based on years of use (1-2, 3-5, 6+), herbal and 
specialty supplement exposure was categorized as “no use” or “any use” over the over the previous 10 
years, based on use reported from individual supplements, mixtures, and multivitamins when indicated. 
Only the 11 herbal and specialty supplements for which at least 5% of participants were users were 
included. 
 
Other participant characteristics and covariates The questionnaire captured numerous 
covariates, including demographic and lifestyle characteristics, health history, medication use with 
emphasis on NSAID use, physical activity over the 10 years prior to baseline, cancer screening 
practices, and other potential confounders of supplement-cancer associations. In these analyses, we 
considered adjustment for socio-demographic characteristics (self-reported age, sex, race, and 
education); lifestyle and behavioral factors (smoking history, physical activity, fruit and vegetable 
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consumption, use of non-fiber laxatives); and anthropometric characteristics (weight, height, and body 
mass index (BMI, kg/m2)). Prior history of cancer, first-degree family history of lung or colorectal 
cancer, sigmoidoscopy/colonoscopy use, self-report of physician-diagnosed COPD and/or asthma, and 
having had a polyp removed were also obtained.  
Smokers were defined as individuals who smoked at least one cigarette per day for at least a 
year and smoking status was defined as never, current, quit 10 years or more or quit less than 10 years 
ago, as of the date of questionnaire completion. Duration of smoking was estimated by the reported 
number of years smoked and intensity by the usual number of cigarettes smoked per day.   
 
Outcome assessment 
Participants were followed for lung and colorectal cancers occurring from baseline through 
December 31, 2006 by linking the cohort to the Seattle-Puget Sound SEER registry. Cases are captured 
through all hospitals in the area, offices of pathologists, oncologists, and radiotherapists, and from 
State death certificates.  Cancer cases were identified in the cohort using matching algorithms on 
personal identifiers and human review (28). 
For each participant, the censored date was the earliest date of withdrawal from the study 
(0.03%), death (3.02%), move out of the SEER catchment area (4.57%), or last date of linkage to the 
SEER registry for remaining participants (December 31, 2006). Deaths were ascertained by linkage to 
Washington State death files, and moves out of the area were identified through the National Change 
of Address System and by follow-up letters and telephone calls. If a participant had multiple diagnoses 
of lung or colorectal cancer, we used the time to first primary diagnosis.   
For these analyses, we excluded 588 and 1184 participants with a self-reported history of lung 
cancer and colorectal cancer, respectively, at baseline (or who did not complete the baseline medical 
history section), 2 individuals whose lung cancer was classified as lymphoma, and 23 colorectal 
cancers with morphologies of large cell/squamous cell/Goblet cell carcinoma, carcinoid tumor, 
neuroendocrine carcinoma or lymphoma, and 4 lung cancer cases who diagnoses was based on death 
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certificate only, leaving 665 lung cancer cases and 76,460 non lung cancer cases, and 428 colorectal 
cancer cases and 76,084 non-colorectal cancer cases. 
 
Statistical analysis 
Data analyses were performed using SAS (version 9.1, 2002-2003, SAS Institute Inc., Cary, 
NC). Cox proportional hazards regression was used to estimate the hazard ratios (HR) for associations 
of the herbal and specialty supplements with lung and colorectal cancer risk. Robust standard errors 
were used in order to eliminate traditional proportional hazards assumptions.  
Lung cancer analyses A priori and using a step-wise procedure, we analyzed variables that 
measured smoking status, duration, and intensity (pack-years, pack-years squared, years of smoking, 
years of smoking squared, smoking status (4 categories as above), and age when started smoking) in a 
Cox model predicting lung cancer risk at a p=0.05 level. Our final model included years smoked, pack-
years, and a squared pack-years term. We also decided a priori to include age and gender in the model. 
Finally, we evaluated whether education (≤high school, some college, college graduate), physical 
activity (quartiles), BMI (underweight, normal, overweight, obese), fruit and vegetable consumption 
(quartiles), previous history of cancer (yes, no), COPD/emphysema/asthma (yes, no), and first-degree 
family history of lung cancer (ye, no) were confounders of the herbal/specialty supplement-lung cancer 
associations in models already adjusted for age, gender, and the smoking variables. These factors did 
not appear to confound associations of the other herbal and specialty products, so the more 
parsimonious models were used. For glucosamine and chondroitin, we further adjusted for NSAID use 
(4+ times per week for 4+ years, yes or no), current multivitamin use (yes, no), and history of arthritis 
(yes, no), as these supplements are often used by persons with osteoarthritis (30).  
Colorectal cancer analyses We evaluated whether education, physical activity, smoking status, 
BMI, fruit and vegetable consumption, use of non-fiber laxatives (never/<1 per year, 1-4 times per 
year, 5-11 times per year, 1-3 times per month, ≥1 time per week), NSAID use, sigmoidoscopy use in 
the past 10 years (yes, no), current multivitamin use, previous history of cancer, and first-degree family 
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history of colorectal cancer (yes, no) were confounders of the herbal/specialty supplements-colorectal 
cancer associations in models already adjusted for age and gender. The final model for all the herbal 
and specialty supplements included age, gender, education, physical activity, BMI, fruit and vegetable 
consumption, NSAID use, and sigmoidoscopy. Glucosamine, chondroitin, and methylsulfonyl methane 
(MSM) were further adjusted for history of arthritis. 
For both lung and colorectal cancers, glucosamine, chondroitin, and MSM were also adjusted 
for each of the other two supplements, as these three compounds are often marketed to be taken 
together (30). These adjustments did not change the results appreciably, so the results presented do not 
reflect adjustment for these supplements. Also, adjusting associations of St. John’s wort’s with 
colorectal cancer for depression (an indication for using the supplement) did not change the results. 
Finally, excluding participants whose cancer was diagnosed within the first year of follow-up did not 
change the results, so the entire study sample was included. 
 
 
RESULTS  
 
Over 77,000 VITAL cohort participants (n=77,125 for lung cancer and n=77,512 for colorectal 
cancer) met the inclusion criteria for these analyses, and were followed for a mean of 5.0 years (SD 
1.01 years). Six hundred and sixty-five participants developed lung cancer, of which 391 (75%) were 
non-small cell lung cancer (NSCLC). Fourteen percent were small cell lung cancer (SCLC) and the 
remaining cancers (11%) included carcinomas not otherwise specified and carcinoid/neuroendocrine 
tumors. Of the NSCLC, 34% were adenocarcinoma (n=226), 17% were squamous cell (n=116), 2% 
were large cell (n=16), and 22% were NSCLC, not otherwise specified (n=143).  
Table 1 gives demographic and other characteristics of lung cancer cases and non-lung cancer 
cases. Relative to non-cases, participants with lung cancer were more likely to be older (67.2 vs. 61.9 
years), male (55% vs. 48%), have a high school education or lower (37% vs. 20%), be current smokers 
(31% vs. 8%), sedentary (24% vs. 15%), consume fewer fruits and vegetables, be NSAID users (34% 
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vs. 26%), have had a prior cancer (30% vs. 20%), COPD/emphysema (17% vs. 3%), and a family 
history of lung cancer (20% vs. 13%), but were less likely to be obese (19% vs. 25%). There were no 
differences in current use of multivitamins or history of arthritis. 
As shown in Table 2, colorectal cancer cases tended to be older (66.3 vs. 61.9 years), obese 
(30% vs. 25%), never smokers (39% vs. 48%), use non-fiber laxatives more frequently (14% vs. 9% at 
1-4 times per year), but were less likely to be have obtained a sigmoidoscopy in the previous 10 years 
(45% vs. 57%). There were no clear differences based on gender, smoking status, physical activity, 
consumption of fruits/vegetables, NSAID use, current multivitamin use, having had a polyp removed, 
arthritis, or family history of colorectal cancer.  
Associations of use of various herbal and specialty supplements with lung cancer risk are given 
in Table 3. Any use of glucosamine and chondroitin during the previous 10 years was statistically 
significantly inversely associated with lung cancer risk: HR: 0.74 (95% CI: 0.58, 0.94, p=0.01) and 
HR: 0.72 (95% CI: 0.54, 0.96, p=0.02), respectively. These associations persisted after control for the 
main adjustment factors in Table 1 (age, gender, education, smoking) as well as history of arthritis (the 
main indication for glucosamine and chondroitin use), NSAID use (another common treatment for 
arthritis), and current multivitamin use. Associations with total lung cancer were comparable for 
NSCLC but were stronger for adenocarcinomas: HR: 0.61 (95% CI: 0.41, 0.92, p=0.02) and HR: 0.50 
(95% CI: 0.30, 0.84, p=0.009) for glucosamine and chondroitin, respectively (data not shown in the 
table). No other herbal or specialty supplements were associated with lung cancer risk.  
Table 4 gives associations of any use of herbal or specialty supplement use over the previous 
10 years with colorectal cancer risk. The strongest associations were for St. John’s wort (HR: 0.35, 
95% CI: 0.14, 0.85, p=0.02) and methylsulfonylmethane or MSM (HR: 0.46, 95% CI: 0.23, 0.93, 
p=0.03) with colorectal risk. Associations were also statistically significant for fish oil (HR: 0.65, 95% 
CI: 0.42, 0.99, p=0.05), glucosamine (HR: 0.72, 95% CI: 0.54, 0.98, p=0.03), and chondroitin (HR: 
0.65, 95% CI: 0.45, 0.93, p=0.02) supplements. In contrast, use of garlic pills was associated with a 
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significant 35% elevated risk (HR: 1.35, 95% CI: 1.01, 1.81, p=0.04). Melatonin was associated with a 
non-statistically significant 42% reduced risk. No other herbal of specialty supplements were 
associated with colorectal cancer risk. 
 
 
DISCUSSION 
 
In this study that examined whether use of various herbal and specialty supplements were 
associated with risk for lung and colorectal cancers, any use of glucosamine and chondroitin 
supplements in the previous 10 years were associated with significantly lower risk for both cancers. In 
addition, use of fish oil, St. John’s wort, melatonin, and MSM supplements were associated with 35-
65% reductions in colorectal rectal cancer risk; whereas garlic pills were associated with significantly 
elevated risk. Because, to our knowledge, there are no observational studies of glucosamine, 
chondroitin, or MSM, and very few of garlic or fish oil in relation to lung and colorectal cancer risk in 
human populations, this makes it challenging to place our findings in the context of the current body of 
knowledge. 
 We were somewhat surprised by the consistent inverse associations of glucosamine and 
chondroitin with lung and colorectal cancer risk, which persisted even after control for various 
demographic and lifestyle factors and health conditions that may be confounders. Glucosamine is made 
from glucose and the amino acid glutamine, is used in the formation and repair of cartilage and other 
body tissues, is found naturally in the body, and its production slows with age (31-35). Glucosamine is 
commonly taken in combination with chondroitin, a glycosaminoglycan derived from articular 
cartilage. Like glucosamine, chondroitin may prevent the breakdown of cartilage and research studies 
(including some randomized trials) suggest that both compounds may also be effective treatments for 
osteoarthritis (31-36).  
While these supplements are most commonly used by patients with osteoarthritis and have been 
studied extensively for purpose, they are not often considered potential preventive agents for cancer. 
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Nonetheless, there are possible mechanisms by which these products may influence the carcinogenic 
process. There is evidence that glucosamine inhibits the interleukin (IL-1) signaling cascade and gene 
expression; specifically, glucosamine appears to inhibit both anabolic and catabolic genes, so its 
potential therapeutic effects (if any) might be due to anti-catabolic activities, which can affect cancer 
development (31, 33-36). Both glucosamine and chondroitin also have anti-inflammatory properties 
(31, 33-36), and there is growing evidence that tissue damage caused by inflammation can initiate or 
promote the development of lung and colorectal cancers and that other anti-inflammatory drugs reduce 
the risk of both lung and colorectal cancer (37). The anti-inflammatory properties of these compounds 
are exhibited through diverse mechanisms such as reducing the expression of phospholipase A2, 
cyclooxygenase-2 (COX-2), and concentrations of prostaglandin E2 (PGE2), reactive oxygen and 
nitrogen species, and pro-inflammatory cytokines such as TNF-α and IL-6 (31, 33-36). In vitro, 
glucosamine sulfate has been demonstrated to reduce prostaglandin E2 (PGE2) production and interfere 
with nuclear factor kappa B (NFκB) DNA binding in chondrocytes and synovial cells (31, 32-36, 38). 
We note that randomized clinical trials of glucosamine and osteoarthritis suggest that the sulfate 
moiety provides clinical benefit in the synovial fluid by strengthening cartilage and aiding 
glycosaminoglycan synthesis, which would indicate that glucosamine sulfate (and not non-sulfated 
glucosamine) form is more effective (31-34). Most specialty formulations of glucosamine used by 
consumers are the sulfate form. Therefore, from a mechanistic perspective, it is plausible that 
glucosamine and chondroitin may reduce risk for lung and colorectal cancers through underlying 
mechanisms. However, additional studies examining these potential associations in human populations 
are needed.  
 Methylsulfonylmethane (MSM) is a sulfur-containing compound normally found in food that is 
often marketed in combination with glucosamine and chondroitin (33,39,40). In the present study, 
MSM was associated with a significant (HR=0.54) decrease in colorectal cancer risk, which was also 
unanticipated. It is chemically related to dimethyl sulfoxide (DMSO), a popular, although unproven, 
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treatment for arthritis that has also been proposed as a treatment for cancer (39,40). In fact, it has been 
suggested that the health benefits associated with DMSO may be due to MSM, which is a breakdown 
by-product of DMSO. Although there is scant support for these hypotheses, it has been suggested that 
DMSO, and by extension, MSM, interferes with cancer development by stimulating various parts of 
the immune system, scavenging free (hydroxyl) radicals, and inhibiting cell growth (39,40). However, 
currently, there is no evidence that MSM is beneficial for cancer or any other health condition. 
As in some other studies (41-43), melatonin was associated with a reduction in colorectal 
cancer risk (42% in the present investigation), although the association was not statistically significant. 
Melatonin is a hormone produced in the brain from the amino acid tryptophan. The synthesis and 
release of melatonin are stimulated by darkness and suppressed by light, and it is well-accepted that it 
is involved in regulatory control of the sleep/wake cycle, as well as circadian rhythms generally 
(42,43). In addition, there is appreciable evidence indicating that melatonin is involved in preventing 
tumor initiation, promotion, and progression; these anticarcinogenic effects appear to be due to its 
antioxidant, immunostimulating, and apoptotic properties (41-43). In in vitro studies and animal 
models, melatonin has been shown to inhibit growth of breast, prostate, liver, hepatoma, and colorectal 
cancer cell lines (41-43). Moreover, melatonin secretion is impaired in patients with some cancers, 
including colorectal cancer, and it has been hypothesized that the somewhat higher incidence of 
colorectal cancer in persons who work the night shift may be due to lower secretion of melatonin and 
increased exposure to light during nighttime (41-43). 
St. John’s wort is one of the most investigated medicinal plants and is a member of the genus 
Hypericum (44). It has been extensively studied as an herbal treatment for depression; however, we are 
not aware of any human studies evaluating a potential link to cancer. Therefore, it is somewhat 
surprising that it was associated with a 65% decrease in risk for colorectal cancer. Potential 
mechanism(s) of action of St. John’s are not known (44). Any anti-carcinogenic activity may be due to 
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antioxidant properties conferred by other biologically active constituents within the plant, such as 
flavonoids and tannins (44).  
It is not unexpected that use of fish oil supplements was associated a statistically significant 
35% lowering of colorectal cancer risk, as they contain omega-3 fatty acids (n-3 PUFAs), 
eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA), precursors to eicosanoids that reduce 
inflammation (45,46). As noted above, uncontrolled inflammatory processes have been linked to 
elevated risk for colorectal cancer (37,45,46). In particular, a variety of experimental studies, clinical 
trials, and observational studies have substantiated a beneficial role of n-3 PUFAs in colorectal cancer, 
largely due to their regulatory roles in cell proliferation and apoptosis and their anti-angiogenic and 
anti-inflammatory properties (37,45,46).  
We were surprised, however, that garlic pills were associated with significantly elevated 
colorectal cancer risk, because animal studies and observational (cohort and case-control) studies have 
suggested a potentially protective role for garlic on colorectal cancer (26, 47-49). Also, a recent 
randomized clinical trial reported a significant suppression in both the total size and number of 
adenomas in colorectal cancer patients (n=37) taking aged garlic extract (49). Any anti-tumor activities 
associated with garlic are believed to be due to its antioxidant properties (47-49). However, it is worth 
noting that while some human studies have demonstrated inverse associations of garlic consumption 
with colorectal cancer risk, there is considerable heterogeneity in assessment/measures of garlic intake, 
types of garlic consumed (e.g., cooked, fresh, extract) and outcome (colorectal cancer, adenoma 
number and/or size).  
Our study has several strengths. We used a comprehensive instrument that captured long-term 
use of 20 different herbal and specialty supplements. The assessment of (long-term) intake during the 
10 years prior to baseline allowed us to more closely investigate herbal and specialty supplement 
exposure over the relevant period of cancer development. Exposure and risk factor ascertainment were 
obtained prior to the diagnosis of cancer and this prospective approach reduced the likelihood of 
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selection bias because potential participants could not choose to take part in the study based on both 
supplement use and future (unknown) cancer diagnosis. We controlled for several factors that affect or 
modify lung and colorectal cancer risk, particularly the strong effects of tobacco smoking (for lung 
cancer), lifestyle/behavioral factors and screening (for colorectal cancer), and the diseases that are 
common indications for use of certain supplements, i.e., confounding by indication. Finally, cancer 
cases were ascertained using a comprehensive linkage system with the SEER registry, which we have 
estimated to be almost 100 percent complete for the year 2006, suggesting that the number of non-
identified cases should be minimal. 
 The study also has some potential limitations. As with other observational studies, there is the 
possibility of uncontrolled or residual confounding. In addition, there is likely some misclassification 
due to self-report of supplement use, although this is unlikely to be differential in a cohort study. 
Finally, we did not have sufficient numbers of herbal or specialty supplement users who developed 
cancer to characterize use other than as no use versus use in the past 10 years. 
In summary, this is one of the first observational epidemiologic studies to 
comprehensively and rigorously examine associations of several commonly used herbal and specialty 
supplements with risks for lung and colorectal cancers. Glucosamine and chondroitin use was 
associated with significantly reduced risk for both tumor types; St. John’s wort, MSM, fish oil, and 
melatonin were inversely associated with colorectal cancer risk, and garlic pills were associated with 
higher risk. While the results of this study are intriguing, possible risks associated with most herbal and 
specialty supplements are not known (14-17). For example, in theory, glucosamine may decrease the 
effectiveness of drugs that lower blood sugar levels and may increase risk of bleeding (31-34). Side 
effects of St. John’s wort include gastrointestinal symptoms, anxiety, fatigue, and drug interactions 
(14,17,44).  Therefore, these supplements should be recommended and used with caution. In addition, 
given their ever-growing popularity, additional human studies examining the possible effects of herbal 
and specialty supplements on risk for cancer and other health conditions are urgently needed. 
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Table 1. Participant characteristics of lung cancer cases and non-lung cancer cases, the VITAL Study (n=77,125) 
 
Characteristic Lung cancer cases (N=665) 
Controls* 
(N=76,460) 
Age at baseline (years)    
   50-59 (n, %) 116 (17) 35,269 (46) 
   60-69 (n, %) 274 (41) 26,481 (35) 
   ≥70 (n, %) 275 (41) 14,710(19) 
        Mean ± SD 67.2 (6.6) 61.9 (7.4) 
   
Gender (n, %)   
     Female 296 (45) 39,777 (52) 
     Male 369 (55) 36,683 (48) 
   
Race (n, %)   
     Non-White 37 (6) 5,138 (7) 
     White 609 (94) 70,009 (93) 
   
Education (n, %)   
     ≤High school education 237 (37) 15,022 (20) 
     Some college 259 (40) 28,776 (38) 
     College graduate/advanced degree 152 (23) 31,369 (42) 
   
Smoking Status (n, %)   
     Never 52 (8) 36,389 (48) 
     Former, quit ≥10 yrs 275 (42) 28,091 (37) 
     Former, quit <10 yrs 128 (19) 4,906 (6) 
     Current 203 (31) 6,220 (8) 
       Pack-years of cigarettes (mean ± SD) 43.4 (27.7) 13.3 (21.0) 
   
Number of years as a smoker (n, %)   
     Non-smokers (0 – 0) 52 (8) 36,389 (48) 
     Lower half of smokers (2.5-24.5) 50 (8) 17,827 (24) 
     Upper half of smokers (25-59) 556 (84) 21,482 (28) 
        Mean (SD) 33.8 (13.9) 11.8 (14.9) 
   
Physical activity (MET-hours per week)   
     No exercise 157 (24) 11,245 (15) 
     1st Quartile (0.01 – 3.03) 145 (22) 16,034 (21) 
     2nd Quartile (3.04 – 8.06) 148 (23) 15,998 (21) 
     3rd Quartile (8.07-17.81) 107 (16) 16,057 (21) 
     4th Quartile (>17.81) 92 (14) 16,073 (21) 
   
BMI Category (kg/m2)   
     Underweight (<18.5) 16 (3) 652 (1) 
     Normal (18.5 - 24.9) 230 (37) 24,334 (33)  
     Overweight (25 - 29.9) 262 (42) 29,796 (41) 
     Obese (≥30) 120 (19) 17,902 (25) 
   
Vegetables (servings/day)   
     1st Quartile (0 – 1.33) 171 (30) 17,242 (25) 
     2nd Quartile (1.34-1.97) 151 (26) 17,231 (25) 
     3rd Quartile (1.98 – 2.88) 139 (24) 17,315 (25) 
     4th Quartile (> 2.88) 110 (19) 17,296 (25) 
   
Fruit (servings/day)   
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     1st Quartile (0 – 0.75) 200 (35) 17,206 (25) 
     2nd Quartile (0.76-1.34) 132 (23) 17,274 (25) 
     3rd Quartile (1.35 – 2.31) 133 (23) 17,281 (25) 
     4th Quartile (>2.31) 104 (18) 17,313 (25) 
   
NSAID use (4+ times/wk, 4+yrs) (n, %)   
     No 430 (66) 55,070 (74) 
     Yes 222 (34) 19,772 (26) 
   
Current use a multivitamin (n, %)†   
     No 291 (44) 32,245 (42) 
     Yes 374 (56) 44,205 (58) 
   
Medical History (n, %)   
Prior cancer   
     No 461 (70) 61,188 (80) 
     Yes 202 (30) 15,272 (20) 
   
COPD or Emphysema   
     No 549 (83) 73,809 (97) 
     Yes 114 (17) 2,633 (3) 
   
Arthritis   
     No 452 (68) 53,739 (70) 
     Yes 211 (32) 22,703 (30) 
   
Family history of lung cancer (n, %)‡   
     No 526 (80) 65,962 (87) 
     Yes 131 (20) 9,495 (13) 
 
 
NOTE: All characteristics had <5% missing data and percentages are of the total. Numbers may not sum to the 
total and percentages may not add up to 100% because of missing data and/or rounding. 
 
*Controls refer to the non-lung cancer cases 
† Multivitamin users who responded “sometimes” were included in the “yes” category 
‡ Family history of colorectal cancer defined as one or more 1st degree relative with lung cancer 
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Table 2. Participant characteristics of colorectal cancer cases and non-colorectal cancer cases, the VITAL Study 
(n=76,512) 
 
Characteristic Colorectal cancer cases (N=428) 
Controls* 
(N=76,084) 
Age at baseline (years)    
   50-59 (n, %) 87 (20) 35,185 (46) 
   60-69 (n, %) 190 (44) 26,336 (35) 
   ≥70 (n, %) 151 (35) 14,563 (19) 
        Mean ± SD 66.3 (6.7) 61.9 (7.4) 
   
Gender (n, %)   
   Female 208 (49) 39,568 (52) 
   Male 220 (51) 36,516 (48) 
   
Race (n, %)   
Non-White 37 (9) 5,083 (7) 
White 383 (91) 69,964 (93) 
   
Education (n, %)   
     ≤High school education 143 (34) 14,969 (20) 
     Some college 146 (35) 28,679 (38) 
     College graduate/advanced degree 132 (31) 31,142 (42) 
   
Smoking Status (n, %)   
Never 163 (39) 35,922 (48) 
Former, quit ≥10 yrs 182 (43) 27,933 (37) 
Former, quit <10 yrs 36 (9) 5,025 (7) 
Current 41(10) 6,352 (8) 
   
Physical activity (MET-hours/week)   
No exercise 68 (16) 11,245 (15) 
1st Quartile (0.01 – 3.02) 105 (25) 15,947 (21) 
2nd Quartile (3.03 – 8.06) 92 (22) 15,928 (21) 
3rd Quartile (8.07-17.81) 72 (17) 15,958 (21) 
4th Quartile (>17.81) 78 (19) 15,959 (21) 
   
BMI Category (kg/m2)   
Underweight (<18.5) 8 (2) 656 (1) 
Normal (18.5 - 24.9) 112 (28) 24,296 (34) 
Overweight (25 - 29.9) 160 (40) 29,636 (41) 
Obese (≥30) 122 (30) 17,747 (25) 
   
Vegetables (servings/day)   
1st Quartile (0 – 1.33) 102 (27) 17,151 (25) 
2nd Quartile (1.34-1.97) 105 (28) 17,168 (25) 
3rd Quartile (1.98 – 2.88) 86 (23) 17,220 (25) 
4th Quartile (> 2.88) 81 (22) 17,179 (25) 
   
Fruits (servings/day)   
1st Quartile (0 – 0.75) 98 (26) 17,178 (25) 
2nd Quartile (0.76-1.34) 98 (26) 17,177 (25) 
3rd Quartile (1.35 – 2.31) 105 (28) 17,157 (25) 
4th Quartile (>2.31) 72 (19) 17,197 (25) 
   
Use of non-fiber laxatives   
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       Never/<1 per year 315 (81) 60,856 (86) 
       1-4 times per year 53 (14) 6,192 (9) 
       5-11 times per year 12 (3) 1,858 (3) 
       1-3 times per month 7 (2) 924 (1) 
       ≥1 time per week 3 (1) 732 (1) 
   
NSAID use (4+ times/wk, 4+yrs) (n, %)   
     No 321 (77) 54,748 (74) 
     Yes 94 (23) 19,736 (26) 
   
Sigmoidoscopy/colonoscopy in the past 10 
years (n, %) 
  
     No 232 (55) 32,641 (43) 
     Yes 191 (45) 42,794 (57) 
   
Current use a multivitamin (n, %)†   
     No 182 (43) 32,100 (42) 
     Yes 246 (57) 43,974 (58) 
   
Medical History (n, %)   
Prior cancer   
       No 312 (73) 61,322 (81) 
       Yes 116 (27) 14,762 (19) 
   
Polyp removed from colon   
      No 370 (86) 66,406 (87) 
      Yes 58 (14) 9,678 (13) 
   
Arthritis         
     No 300 (70) 53,469 (70) 
     Yes 128 (30) 22,598 (30) 
   
Family history of colorectal cancer (n, %)‡   
      No 354 (85) 66,534 (89) 
      Yes 63 (15) 8,556 (11) 
 
 
NOTE: All characteristics had <5% missing data and percentages are of the total. Numbers may not sum to the 
total and percentages may not add up to 100% because of missing data and/or rounding. 
 
*Controls refer to the non-colorectal cancer cases 
† Multivitamin users who responded “sometimes” were included in the “yes” category 
‡ Family history of colorectal cancer defined as one or more 1st degree relative with colorectal cancer 
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Table 3. Associations of lung cancer risk with use of various herbal and specialty supplements during the previous 
10 years, the VITAL Study (n=77,125) 
 
Herbal or specialty supplement* Lung cancer cases 
(N=665) 
 
N (%) 
Non-lung cancer 
cases 
(N=76,460) 
 
N (%) 
Adjusted hazard 
ratio† 
(Adjusted 95% CI†2) 
 
Fish oil    
   No use 608 (91) 68,760 (90) 1.00 (Ref) 
   Any pills per day during the previous 10 years 57 (9) 7,453 (10) 1.09 (0.83, 1.44) 
   User v Non-User p   0.52 
    
Garlic pills    
   No use 582 (88) 67,204 (88) 1.00 (Ref) 
   Any pills per day during the previous 10 years 80 (12) 8,950 (12) 1.05 (0.83, 1.34) 
   User v Non-User p   0.66 
    
Gingko biloba    
   No use 584 (88) 65,753 (86) 1.00 (Ref) 
   Any pills per day during the previous 10 years 80 (12) 10,411 (14) 1.04 (0.82, 1.32) 
   User v Non-User p   0.76 
    
Ginseng    
   No use 620 (94) 69,888 (92) 1.00 (Ref) 
   Any pills per day during the previous 10 years 43 (6) 6,322 (8) 0.97 (0.70, 1.33) 
   User v Non-User p   0.93 
    
Grapeseed    
   No use 631 (95) 70,512 (92) 1.00 (Ref) 
   Any pills per day during the previous 10 years 33 (5) 5,786 (8) 0.97 (0.68, 1.38) 
   User v Non-User p   0.86 
    
Glucosamine‡    
   No use 576 (87) 60,733 (80) 1.00 (Ref) 
   Any pills per day during the previous 10 years 88 (13) 15,458 (20) 0.74 (0.58, 0.94) 
   User v Non-User p   0.01 
    
Chondroitin‡    
   No use 609 (92) 65,789 (86) 1.00 (Ref) 
   Any pills per day during the previous 10 years 55 (8) 10,368 (14) 0.72 (0.54, 0.96) 
   User v Non-User p   0.02 
    
Melatonin    
   No use 638 (96) 72,449 (95) 1.00 (Ref) 
   Any pills per day during the previous 10 years 26 (4) 3,799 (5) 0.99 (0.66, 1.47) 
   User v Non-User p   0.95 
    
Methylsulfonylmethane (MSM)    
   No use 636 (96) 72,640 (95) 1.00 (Ref) 
   Any pills per day during the previous 10 years 29 (4) 3,675 (5) 1.00 (0.68, 1.47) 
   User v Non-User p   0.99 
    
St. John’s wort    
   No use 638 (96) 72,375 (95) 1.00 (Ref) 
   Any pills per day during the previous 10 years 24 (4) 3,868 (5) 0.98 (0.65, 1.48) 
   User v Non-User p   0.94 
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Saw palmetto§    
   No use 335 (90) 32,564 (89) 1.00 (Ref) 
   Any pills per day during the previous 10 years 34 (10) 4,043 (11) 0.84 (0.59, 1.21) 
   User v Non-User p   0.36 
 
NOTE: Only herbal or specialty supplements for which at least 5% of either cases or non-cases were users are included. 
 Numbers may not sum to the total and percentages may not add up to 100% because of missing data and/or rounding. 
 
*Based on self-reported intakes from the individual supplements, mixtures, and from multivitamins, when relevant  
†Adjusted for age, gender, education, years smoked, packyears, and packyears squared 
‡Adjusted for age, gender, education, years smoked, packyears, packyears squared, NSAID use, history of arthritis, and 
multivitamin use. Also, glucosamine, chondroitin, and MSM were adjusted for each of the other two supplements. 
§Saw palmetto was asked of men only 
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Table 4. Associations of colorectal cancer risk with use of various herbal and specialty supplements during the 
previous 10 years, the VITAL Study (n=76,512) 
 
Herbal or specialty supplement* Colorectal cancer cases 
(N=428) 
 
N (%) 
Non-colorectal 
cancer cases 
(N=76,084) 
 
N (%) 
Adjusted hazard 
ratio† 
(Adjusted 95% CI†) 
 
Fish oil    
   No use 399 (93) 68,417 (90) 1.00 (Ref) 
   Any pills per day during the previous 10 years 28 (7) 7,424 (10) 0.65 (0.42, 0.99) 
   User v Non-User p   0.05 
    
Garlic pills    
   No use 358 (84) 66,893 (88) 1.00 (Ref) 
   Any pills per day during the previous 10 years 70 (16) 8,883 (12) 1.35 (1.01, 1.81) 
   User v Non-User p   0.04 
    
Gingko biloba    
   No use 377 (88) 65,146 (86) 1.00 (Ref) 
   Any pills per day during the previous 10 years 49 (12) 10,373 (14) 0.83 (0.59, 1.17) 
   User v Non-User p   0.29 
    
Ginseng    
   No use 397 (93) 69,528 (92) 1.00 (Ref) 
   Any pills per day during the previous 10 years 29 (7) 6,309 (8) 0.86 (0.56, 1.33) 
   User v Non-User p   0.50 
    
Grapeseed    
   No use 406 (95) 70,177 (92) 1.00 (Ref) 
   Any pills per day during the previous 10 years 22 (5) 5,746 (8) 0.72 (0.44, 1.18) 
   User v Non-User p   0.19 
    
Glucosamine‡    
   No use 360 (85) 60,444 (80) 1.00 (Ref) 
   Any pills per day during the previous 10 years 66 (15) 15,373 (20) 0.73 (0.54, 0.98) 
   User v Non-User p   0.03 
    
Chondroitin‡    
   No use 385 (90) 65,556 (86) 1.00 (Ref) 
   Any pills per day during the previous 10 years 42 (10) 10,316 (14) 0.65 (0.45, 0.93) 
   User v Non-User p   0.02 
    
Melatonin    
   No use 410 (96) 72,080 (95) 1.00 (Ref) 
   Any pills per day during the previous 10 years 15 (4) 3,794 (5) 0.58 (0.30, 1.13) 
   User v Non-User p   0.11 
    
Methylsulfonylmethane (MSM)‡    
   No use 415 (97) 72,262 (95) 1.00 (Ref) 
   Any pills per day during the previous 10 years 13 (3) 3,678 (5) 0.46 (0.23, 0.93) 
   User v Non-User p   0.03 
    
St. John’s wort    
   No use 418 (98) 72,000 (95) 1.00 (Ref) 
 30
   Any pills per day during the previous 10 years 8 (2) 3,866 (5) 0.35 (0.14, 0.85) 
   User v Non-User p   0.02 
    
Saw palmetto§    
   No use 194 (88) 32,424 (89) 1.00 (Ref) 
   Any pills per day during the previous 10 years 26 (12) 4,017 (11) 1.01 (0.65, 1.58) 
   User v Non-User p   0.97 
 
NOTE: Only herbal or specialty supplements for which at least 5% of either cases or non-cases were users are included. 
Numbers may not sum to the total and percentages may not add up to 100% because of missing data and/or rounding. 
 
*Based on self-reported intakes from the individual supplements, mixtures, and from multivitamins, when relevant  
†Adjusted for age, gender, education, physical activity, fruit and vegetable consumption, body mass index, NSAID use, and 
sigmoidoscopy. 
‡Adjusted for age, gender, education, physical activity, fruit and vegetable consumption, body mass index, NSAID use, 
sigmoidoscopy, history of arthritis. Also, glucosamine, chondroitin, and MSM were adjusted for each of the other two 
supplements. 
§Saw palmetto was asked of men only 
